Y
Yutaka Kanda
Researcher at Kyowa Hakko Kirin Co., Ltd.
Publications - 36
Citations - 3558
Yutaka Kanda is an academic researcher from Kyowa Hakko Kirin Co., Ltd.. The author has contributed to research in topics: Antibody & In vivo. The author has an hindex of 17, co-authored 36 publications receiving 3395 citations.
Papers
More filters
Journal ArticleDOI
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.
Toyohide Shinkawa,Kazuyasu Nakamura,Naoko Yamane,Emi Shoji-Hosaka,Yutaka Kanda,Mikiko Sakurada,Kazuhisa Uchida,Hideharu Anazawa,Mitsuo Satoh,Motoo Yamasaki,Nobuo Hanai,Kenya Shitara +11 more
TL;DR: The results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Patent
Cells producing antibody compositions
Yutaka Kanda,Mitsuo Satoh,Kazuyasu Nakamura,Kazuhisa Uchida,Toyohide Shinkawa,Naoko Yamane,Emi Hosaka,Kazuya Yamano,Motoo Yamasaki,Nobuo Hanai +9 more
TL;DR: In this article, a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the anti-antibody or the like.
Journal ArticleDOI
Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA
Katsuhiro Mori,Reiko Kuni-Kamochi,Naoko Yamane-Ohnuki,Masako Wakitani,Kazuya Yamano,Harue Imai,Yutaka Kanda,Rinpei Niwa,Shigeru Iida,Kazuhisa Uchida,Kenya Shitara,Mitsuo Satoh +11 more
TL;DR: It is demonstrated that constitutive FUT8 siRNA expression can control the oligosaccharide structure of recombinant antibody produced by CHO cells to yield antibodies with dramatically enhanced ADCC.
Journal ArticleDOI
Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC
Yutaka Kanda,Naoko Yamane-Ohnuki,Naoto Sakai,Kazuya Yamano,Ryosuke Nakano,Miho Inoue,Hirofumi Misaka,Shigeru Iida,Masako Wakitani,Yoshinobu Konno,Keiichi Yano,Kenya Shitara,Shinji Hosoi,Mitsuo Satoh +13 more
TL;DR: The results demonstrate that FUT8 knockout has the essential characteristics of host cells for robust manufacture of fucose‐negative therapeutic antibodies with enhanced ADCC.
Journal ArticleDOI
A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques
Brian Moldt,Mami Shibata-Koyama,Eva G. Rakasz,Niccole Schultz,Yutaka Kanda,D. Cameron Dunlop,Samantha L. Finstad,Chenggang Jin,Gary Landucci,Michael D. Alpert,Anne-Sophie Dugast,Paul W. H. I. Parren,Falk Nimmerjahn,David T. Evans,Galit Alter,Donald N. Forthal,Jörn E. Schmitz,Shigeru Iida,Pascal Poignard,Pascal Poignard,David I. Watkins,Ann J. Hessell,Ann J. Hessell,Dennis R. Burton,Dennis R. Burton +24 more
TL;DR: A nonfucosylated variant of b12 (NFb12) was developed and it was shown that, compared to fully fucOSylated b12, NFb12 had higher affinity for human and rhesus macaque FcγRIIIa and was more efficient in inhibiting viral replication and more effective in killing HIV-infected cells in an ADCC assay.